CSIMarket Company Name, Ticker, Competitors, else..
 
Purple Biotech Ltd  (NASDAQ: PPBT)
 
Price: $1.6700 $-0.07 -4.023%
Day's High: $1.7100000381469727 Week Perf: -4.57 %
Day's Low: $ 1.62 30 Day Perf: 12.84 %
Volume (M): 71,647 52 Wk High: $ 14.10
Volume (M$): $ 0 52 Wk Avg: $4.61
Open: $1.71 52 Wk Low: $1.16



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees 4
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 7
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Purple Biotech Ltd is a biotechnology company that focuses on developing innovative therapies for a range of medical conditions. The company's primary goal is to harness the power of cellular therapies to address various diseases and improve patient outcomes. Purple Biotech is known for its cutting-edge research and development efforts to create personalized medicine and targeted therapies. With a dedicated team of scientists and medical professionals, the company aims to bring groundbreaking advancements to the field of biotechnology and make a positive impact on patients' lives.


   Company Address: 4 Oppenheimer Street Rehovot 7670104
   Company Phone Number: 3-933-3121   Stock Exchange / Ticker: NASDAQ PPBT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Purple Biotechs IM1240 Production Milestone Marks a New Era in Cancer Therapy Development,

Published Wed, Oct 29 2025 12:27 PM UTC

Purple Biotech Celebrates Manufacturing Milestone for IM1240: A Tri-Specific Antibody from the CAPTN-3 Platform Purple Biotech, a leading biopharmaceutical company focused on developing innovative therapies for cancer treatment, has made significant strides with its latest achievement in the manufacturing of IM1240, a tri-specific antibody derived from the CAPTN-3 platform. ...
Announcement

Purple Biotechs NT219 Poised to Elevate Cancer Treatment with New European Patent and Promising Phase 2 Stud...

Published Wed, Sep 10 2025 12:32 PM UTC

Purple Biotech s Groundbreaking Patent Intent and Phase 2 Study: A New Era in Cancer Treatment Recently, Purple Biotech announced the significant news of receiving an intention to grant a European patent that covers its innovative compound, NT219, particularly when used in combination with immunotherapies or MEK inhibitors. This advancement is crucial as it aims to address t...
Announcement

Purple Biotech Unveils Promising Phase 2 Data at AACR 2025 A Beacon of Hope in Pancreatic Cancer Treatment

Published Wed, Apr 30 2025 11:33 AM UTC

In a significant development for the field of oncology, Purple Biotech Ltd, a pioneering company based in Rehovot, Israel, has revealed final data from its Phase 2 clinical study of CM24 in patients with pancreatic cancer. This announcement, made at the prestigious Annual Meeting of the American Association for Cancer Research (AACR) on April 30, 2025, underscores the potent...
Shares

Purple Biotech: Strategic Capital Raise Aims to Propel Next-Generation Cancer Therapies

Published Thu, Dec 5 2024 12:13 PM UTC

Rehovot, Israel, December 5, 2024 In a move that underscores its commitment to advancing innovative cancer therapies, Purple Biotech Ltd. (NASDAQ/TASE: PPBT) has successfully closed a registered direct offering for 472,668 of its American Depositary Shares (ADSs). The offering comes at a purchase price of $6.00 per ADS, a strategic decision that reflects the company’s ro...
Announcement

Purple Biotech Promising Oncology Developments Amidst Financial Growth

Published Tue, Sep 10 2024 11:00 AM UTC

: Purple Biotech Ltd. continues to make strides in the oncology space, specifically with its lead drug candidate, CM24, which is set to be discussed at the upcoming American Association for Cancer Research (AACR) Special Conference on Advances in Pancreatic Cancer Research. This article reviews the financial performance of the company, particularly its return on assets (ROA)...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.03
PEG (TTM) -

Financial Strength Current
Quick Ratio -
Working Capital Ratio -
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 53.16 $
Book Value 58.9 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) 1,819,750
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 18.6 %
Return On Investment (TTM) 26.86 %
Return On Equity (TTM) 26.86 %
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.